



# OPTO CIRCUITS (INDIA) LIMITED. (UNIT II) 100% EOU



3rd March 2011

**The Manager  
National Stock Exchange  
Exchange Plaza, Bandra Kurla Complex,  
Bandra East, Mumbai 400051**

Dear Sir,

**Subject:** Press Release on study results of Valentines Trial I

We would like to inform you that Opto Circuits (India) Ltd.'s Germany-based subsidiary – Eurocor GmbH has announced study results of Valentines Trial I.

A press release on the same has been enclosed.

Thank you.

Yours faithfully,  
for Opto Circuits (India) Ltd.

Authorised signatory

**Press Release****Opto Circuits' subsidiary Eurocor announces Study results of Valentines Trial I**

- **DIOR® (DEB) shows effective and safe treatment for cases of In-Stent Restenosis (ISR)**
- **Database with largest group of patients ever enrolled to show effectiveness of DEB in treatment of ISR**

**Washington DC, USA | Bonn, Germany | Bengaluru, India, March 3, 2011**

Eurocor GmbH, the Bonn-based subsidiary of Opto Circuits (India) Ltd; presented the first eight month follow-up data from the Valentines Trial I Global Registry on March 1st 2011 during the CRT 2011 Meeting. Eurocor's groundbreaking Valentines Trial I was conducted with an objective to assess the efficacy of the paclitaxel-eluting balloon Dior®- II for In-stent Restenosis (ISR) following Bare Metal Stent (BMS) and Drug-eluting Stent (DES) implantation at 6-9 months. 300 patients (those suffering from ISR) were enrolled by 96 Investigators from 26 countries starting 14th February 2010 and the initial eight-month follow-up data was announced Tuesday by principal investigator Prof. Dr. Sigmund Silber of Munich, Germany during the Conference. This landmark clinical study represents the largest group of patients ever enrolled in a study on the effectiveness of DEB in the treatment of ISR.

**The Results:** The eight-month results very clearly and convincingly showed that the DIOR® DEB is a very effective and safe treatment for cases of in-stent restenosis, both for bare-metal (BMS) and Drug-eluting (DES) devices. The treatment with DIOR® DEB resulted in very low Target Lesion Revascularization (TLR) rates of 7.4% on average, 5.9% for bare-metal stents and 9.8% for Drug-eluting stents. This compares to TLR rates of up to 20% for vascular brachytherapy. The study results further showed DIOR® DEB to be effective in patients that suffer from diabetes with a TLR rate of an average of 11.5%.

"Single digit TLR rates for the treatment of both BMS and DES for in-stent restenosis, this is a very remarkable result, especially taking into consideration the profound disease the patients suffer from." **Prof. Dr. Sigmund Silber** pointed out during the presentation.

"It has been a major challenge to compile this innovative study design. We are thankful and proud that all went well. I am sure the investigators and eurocor have developed a database which will impact treatment and help patients to recover from Cardiovascular disease" **Dr. Rembert Pogge von Strandmann**, Director Clinical & Regulatory; Scientific PR commented.

**Management Comments:** Vinod Ramnani, Chairman and Managing Director, Opto Circuits (India) Ltd. - the parent company of Eurocor GmbH: "We are extremely pleased with the results of the initial eight month follow-up in this landmark clinical study. DIOR® has performed impressively for a very demanding indication and in a difficult patient group. We are committed to further increase the clinical database of patients treated with our innovative and proprietary Drug-eluting balloon products DIOR® and FREEWAY® and have already commenced enrollment in Valentines Trial II aimed at de-novo lesion indications for DIOR®."

**Detailed Trial Results available at:** <http://www.valentines-trial.com/>



**About: DIOR®**

DIOR® is a patent-pending drug (paclitaxel) -eluting breakthrough balloon dilatation catheter developed by scientists at Eurocor and used by hundreds of interventional cardiologists across the world. It can be effectively used in patients with in-stent restenosis, bifurcation lesions and lesions in small vessels. More information available at: [http://www.eurocor.de/products/dior/product\\_information/](http://www.eurocor.de/products/dior/product_information/)

**About: Eurocor GmbH**

Eurocor GmbH is a rapidly growing European Life Sciences Technology Corporation specializing in the research, development and manufacture of cardiovascular and endovascular products. Eurocor is providing interventional cardiologists with innovative, coronary stent technologies and special cardiovascular and endovascular devices. The products manufactured by the company in Bonn are used in minimally invasive cardiovascular and peripheral surgery and comply with biological and biomechanical principles to offer highly flexible, adaptable solutions. Strong research and development, close collaboration with clinicians, outstanding quality standard philosophy and global scientific alliances lead to optimization of clinically effective technologies. Eurocor has designed an innovative method for the delivery of drugs via a balloon catheter that is particularly compatible to the patient. Eurocor GmbH is a subsidiary of Opto Circuits (India) Ltd.

For more information, please visit [www.eurocor.de](http://www.eurocor.de).

**About: Opto Circuits (I) Ltd.**

Headquarters: Bengaluru, Karnataka, India

BSE: 532391 | NSE: OPTOCIRCU

Website: [www.optoindia.com](http://www.optoindia.com)

Opto Circuits (India) Ltd. (OCI) is an MNC in the business of design, development, manufacture and marketing of healthcare equipment and medical interventional products. The product profile includes USFDA-listed, CE-marked cardiac and vital signs monitoring systems, anesthesia and respiratory care equipment, automated external defibrillators, stents, catheters, body implants and consumables. Some of OCI's well-known brands are Cardiac Science, Criticare, Eurocor, Ormed, Mediaid and Unetixs Vascular. The company's key markets are North America, Europe and BRIC countries.

**Contact**

Eurocor GmbH

Claudia Tischendorf

Phone: +49 (0) 228 201 50 26

Email: [pressoffice@eurocor.de](mailto:pressoffice@eurocor.de)

Opto Circuits (India) Ltd.

Phone: +91 80 2852 8088

E: Media - [media@optoindia.com](mailto:media@optoindia.com); Investors: [ir@optoindia.com](mailto:ir@optoindia.com)

